Data / Drug companies / Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated: 21 products in the FDA NDC directory, labeler code 51167
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Vertex Pharmaceuticals Incorporated (labeler code 51167) lists 21 products in the FDA National Drug Code Directory, covering 7 finished drugs by generic name. By type: 20 prescription drugs, 1 cellular therapies. Its main marketing category is new drug applications (NDA). The newest product started marketing on January 30, 2025.
The request: Watch Vertex Pharmaceuticals Incorporated (FDA labeler code 51167): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 51167
- Products in commercial distribution
- 21
- Packages
- 25
- Finished drugs by generic name
- 7
- Prescription products
- 20
- Over the counter products
- 0
- Flagged as original packager
- 20 of 20 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- January 31, 2012
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 20 | 95.2% |
| Biologics (BLA) | 1 | 4.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 20 | 95.2% |
| Cellular therapies | 1 | 4.8% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Ivacaftor | 6 | 1 |
| Lumacaftor and ivacaftor | 5 | 1 |
| Elexacaftor, tezacaftor, and ivacaftor | 4 | 1 |
| Tezacaftor and ivacaftor | 2 | 1 |
| Vanzacaftor, tezacaftor, and deutivacaftor | 2 | 1 |
| Suzetrigine | 1 | 2 |
| Exagamglogene autotemcel | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Granule | 8 | 38.1% |
| Kit | 6 | 28.6% |
| Tablet, film coated | 6 | 28.6% |
| Injection, suspension | 1 | 4.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Cystic Fibrosis Transmembrane Conductance Regulator Potentiator | 13 |
| Sodium Channel Blocker | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Journavx | 51167-548 | Tablet, film coated | New drug applications (NDA) | January 30, 2025 |
| Alyftrek | 51167-135 | Tablet, film coated | New drug applications (NDA) | December 20, 2024 |
| Alyftrek | 51167-121 | Tablet, film coated | New drug applications (NDA) | December 20, 2024 |
| Casgevy | 51167-290 | Injection, suspension | Biologics (BLA) | December 8, 2023 |
| Kalydeco | 51167-785 | Granule | New drug applications (NDA) | May 3, 2023 |
| Kalydeco | 51167-770 | Granule | New drug applications (NDA) | May 3, 2023 |
| Trikafta | 51167-446 | Kit | New drug applications (NDA) | April 26, 2023 |
| Trikafta | 51167-445 | Kit | New drug applications (NDA) | April 26, 2023 |
| Orkambi | 51167-122 | Granule | New drug applications (NDA) | September 2, 2022 |
| Trikafta | 51167-106 | Kit | New drug applications (NDA) | June 8, 2021 |
| Trikafta | 51167-331 | Kit | New drug applications (NDA) | October 21, 2019 |
| Symdeko | 51167-113 | Kit | New drug applications (NDA) | June 21, 2019 |
| Kalydeco | 51167-600 | Granule | New drug applications (NDA) | April 29, 2019 |
| Orkambi | 51167-900 | Granule | New drug applications (NDA) | August 7, 2018 |
| Orkambi | 51167-500 | Granule | New drug applications (NDA) | August 7, 2018 |
| Symdeko | 51167-661 | Kit | New drug applications (NDA) | February 12, 2018 |
| Orkambi | 51167-700 | Tablet, film coated | New drug applications (NDA) | September 28, 2016 |
| Orkambi | 51167-809 | Tablet, film coated | New drug applications (NDA) | July 2, 2015 |
| Kalydeco | 51167-400 | Granule | New drug applications (NDA) | March 23, 2015 |
| Kalydeco | 51167-300 | Granule | New drug applications (NDA) | March 23, 2015 |
| Kalydeco | 51167-200 | Tablet, film coated | New drug applications (NDA) | January 31, 2012 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.